Receptor-Based Virtual Screening of EGFR Kinase Inhibitors from the NCI Diversity Database
Napat Songtawee
Molecules, 2010
View PDFchevron_right
Faculty of 1000 evaluation for Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Gosia Garstka
F1000 - Post-publication peer review of the biomedical literature, 2010
View PDFchevron_right
Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
Luca Mologni
Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
View PDFchevron_right
In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features
Yirong Mo
Drug Design, Development and Therapy, 2013
View PDFchevron_right
Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening
Xianqiang Sun
Bioorganic & medicinal chemistry …, 2012
View PDFchevron_right
Start selective and rigidify: The discovery path towards a next generation of EGFR tyrosine kinase inhibitors
Biljana Peric Simov
Journal of Medicinal Chemistry
View PDFchevron_right
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors
Flavio Solca
Journal of Medicinal Chemistry, 2019
View PDFchevron_right
Hit discovery of 4-amino-N-(4-(3-(trifluoromethyl)phenoxy)pyrimidin- 5-yl)benzamide: A novel EGFR inhibitor from a designed small library
Ahmed Elkamhawy
View PDFchevron_right
In-silico study of potential antiviral drug compounds against EGFR kinase domain to target non-small cell lung cancer (NSCLC)
Ankita Pati
GSC Biological and Pharmaceutical Sciences
View PDFchevron_right
Virtual screening of natural compounds as inhibitors of EGFR 696-1022 T790M associated with non-small cell lung cancer
Mahesha Nand
Bioinformation, 2016
View PDFchevron_right
Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment
REVISTA CIENCIAS BIOMEDICAS
Cribado virtual de Análogos de Osimertinib y Dacomitinib con actividad potencial sobre el receptor de factor de crecimiento epidérmico EGFR (MUTACIONES T790M Y L858R) para el tratamiento del cáncer de pulmón no microcítico, 2021
View PDFchevron_right
Development of triple mutant T790M/C797S allosteric EGFR inhibitors: a computational approach
Prasad Burra
Journal of Biomolecular Structure and Dynamics, 2020
View PDFchevron_right
In Silico Identification of Novel Egfr Tyrosine Kinase Inhibitors Associated with Non-Small Cell Lung Cancer from Phytochemical Library
Mahesha Nand
International Research Journal of Pharmacy, 2016
View PDFchevron_right
Design of EGFR kinase inhibitors: A ligand-based approach and its confirmation with structure-based studies
Gopalakrishnan Bulusu
Bioorganic & medicinal …, 2003
View PDFchevron_right
Exploring the interaction between epidermal growth factor receptor tyrosine kinase and some of the synthesized inhibitors using combination of in-silico and in-vitro cytotoxicity methods
Mahboubeh Mansourian
Research in Pharmaceutical Sciences
View PDFchevron_right
Identification of Potent Inhibitors Targeting EGFR and HER3 for Effective Treatment of Chemoresistance in Non-Small Cell Lung Cancer
Sumera Zaib
Molecules
View PDFchevron_right
Quinoxalinones as A Novel Inhibitor Scaffold for EGFR (L858R/T790M/C797S) Tyrosine Kinase: Molecular Docking, Biological Evaluations, and Computational Insights
Utid Suriya
Molecules
View PDFchevron_right
Towards predictive inhibitor design for the EGFR autophosphorylation activity
Amor San Juan
2008
View PDFchevron_right
Recent progress on third generation covalent EGFR inhibitors
B. Murray
View PDFchevron_right
Abstract 2585: Discovery of a potent covalent mutant-selective EGFR inhibitor - the journey from high throughput screening to EGF816
Matthew McNeill
Cancer Research, 2015
View PDFchevron_right
Identification of Potential Novel Egfr Inhibitors Using a Combination of Pharmacophore and Docking Methods
Urmila Joshi
International Journal of Pharmacy and Pharmaceutical Sciences, 2015
View PDFchevron_right
Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs
Shunzhou Wan
Journal of The Royal Society Interface, 2011
View PDFchevron_right
Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors
mahaveer singh
Drug Discovery Today, 2018
View PDFchevron_right
C -2 ( E )-4-(Styryl)aniline substituted diphenylpyrimidine derivatives (Sty-DPPYs) as specific kinase inhibitors targeting clinical resistance related EGFR T790M mutant
Yang Ge
Bioorganic & Medicinal Chemistry, 2017
View PDFchevron_right
Molecular docking, MM/GBSA and 3D-QSAR studies on EGFR inhibitors
Vijjulatha Manga
Journal of Chemical Sciences, 2016
View PDFchevron_right
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation
Jeffrey Simard
Cancer research, 2010
View PDFchevron_right
Noncovalent wild-type-sparing inhibitors of EGFR T790M
Valentina Pirazzoli
Cancer Discovery, 2013
View PDFchevron_right
Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation
Christine Tam
Journal of Medicinal Chemistry, 2014
View PDFchevron_right
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Robert Padera
Nature, 2009
View PDFchevron_right
EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivatives
Mohamed Elkerdawy
EXCLI journal, 2014
View PDFchevron_right
mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2′,4′-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications
Hsu-Shan Huang
Frontiers in Oncology, 2021
View PDFchevron_right
Structure-based virtual screening, pharmacokinetic prediction, molecular dynamics studies for the identification of novel EGFR inhibitors in breast cancer
Tanushri Kaul
Journal of Biomolecular Structure and Dynamics, 2020
View PDFchevron_right
Structural identification of novel pyrimidine derivatives as epidermal growth factor receptor inhibitors using 3D QSAR, molecular docking, and MMGBSA analysis: a rational approach in anticancer drug design
Ratnesh Das
Mediterranean Journal of Chemistry, 2023
View PDFchevron_right
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors
Kyungik Lee
European Journal of Medicinal Chemistry, 2010
View PDFchevron_right
Virtual Screening and Synthesis of New Chemical Scaffolds as VEGFR-2 Kinase Inhibitors
mohamed elsayed
Arzneimittelforschung, 2012
View PDFchevron_right